Chronic Obstructive Pulmonary Disease

Pharmacotherapy

Volumn 24, Issue 5 II, 2004, Pages

  MacIntyre Jr , Neil R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Corticosteroids; Pulmonary rehabilitation

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CILOMILAST; CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE; MUCOLYTIC AGENT; MUSCARINIC M3 RECEPTOR; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; RETINOIC ACID; RETINOID; ROFLUMILAST; SALBUTAMOL; TIOTROPIUM BROMIDE; VASODILATOR AGENT;

AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTIFICIAL VENTILATION; ASTHMA; BACTERIAL PNEUMONIA; CAUSE OF DEATH; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG HALF LIFE; HAEMOPHILUS INFLUENZAE; HUMAN; LUNG EDEMA; LUNG EMPHYSEMA; LUNG FUNCTION TEST; LUNG RESECTION; LUNG TRANSPLANTATION; MORAXELLA CATARRHALIS; NAUSEA; NERVOUSNESS; NONHUMAN; OXYGEN THERAPY; PATIENT EDUCATION; PRACTICE GUIDELINE; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; RAT; RISK FACTOR; SMOKING CESSATION; STREPTOCOCCUS PNEUMONIAE; TACHYCARDIA; UNITED STATES; VIRUS PNEUMONIA;

EID: 2342642784     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.7.33S.34756     Document Type: Conference Paper

References (39)

1. Altose MD. Approaches to slowing the progression of COPD. Curr Opin Pulm Med 2003;9:125-30.
2. Expert Panel for the Global Initiative for Chronic Obstructive Lung Disease. Could it be COPD? Available from http://www.goldcopd.com. Accessed November 15, 2003.
3. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization global initiative for chronic obstructive lung disease (GOLD executive summary), Respir Care 2001;46:798-825.
4. Bellone PN, Garvin L, Mao CP, Bailey-Healy I, Leaffer D. Effects of all-trans-retinoic acid in promoting alveola repair. Chest 2000;117:S235-41.
5. Quillen DM. COPD: an overview of the GOLD guidelines. Available from http://medscape.com/viewarticle/420891. Accessed November 14, 2003.
6. Carter R, Blevins W, Stocks J, Klein R, Idell S. Cost and quality issues related to the management of COPD. Semin Respir Crit Care Med 1999;20:199-212.
7. American College of Chest Physicians and American Association of Cardiovascular and Pulmonary Rehabilitation, Pulmonary Rehabilitation Guidelines Panel. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. Chest 1997;112:1363-96.
8. American Lung Association. Fact sheet: chronic obstructive pulmonary disease (COPD). Available from http://www. lungusa.org/diseases/copd_factsheet.html Accessed November 14, 2003.
9. National Heart, Lung, and Blood Institute. Morbidity and mortality: 2000 chartbook on cardiovascular, lung, and blood diseases. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2000.
10. Blanchard AR. Treatment of acute exacerbations of COPD. Clin Cornerstone 2003;5:28-36.
11. Rodriguez-Roisin R. Toward a consensus definition of COPD exacerbations. Chest 2000;117(5 suppl 2):S398-401.
12. Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995;274:1852-7.
13. Leatherman NE, Burker EJ, MacIntyre NR. Psychological outcomes of a pulmonary rehabilitation program. Chest 1991;100:613-17.
14. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-9.
15. Faulkner MA, Hilleman D. Pharmacologic treatment of chronic obstructive pulmonary disease: past, present, and future. Pharmacotherapy 2003;23:1300-15.
16. Beeh K, Welte T, Buhl R. Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration 2002;69:372-9.
17. Oga T, Nishimura K, Tuskino M, Sato M, Hajiro T, Mishima M. A comparison of the effects of salbutamol and ipratropium bromide on exercise endurance in patients with COPD. Chest 2203;123:1810-16.
18. Rennard SI, Serby CW, Ghafouri PA, Freidman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: a retrospective analysis of data from seven clinical trials. Chest 1996;110:62-70.
19. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. Ann Intern Med 1991;114:216-23.
20. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med 1999;340:1948-53.
21. Vestobo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effects of inhaled budesonide in patients with moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999;353:1819-23.
22. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomized, double-blind, placebo controlled study of fluticasone proprionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
23. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2002;343:1902-9
24. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-4.
25. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease (Cochrane review). In: The Cochrane library, 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.
26. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy group in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-8.
27. The Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;28:681-6.
28. Crockett AJ, Cranston JM, Moss JR, Alpers JH. A review of long-term oxygen therapy for chronic obstructive pulmonary disease. Respir Med 2001;95:437-43.
29. Meecham-Jones DJ, Paul EA, Jones PW. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med 1995;152:538-44.
30. National Heart, Lung, and Blood Institute. National emphysema treatment trial (NETT): evaluation of lung volume reduction surgery for emphysema. Available from http://www.nhlbi.nih.gov/health/prof/nett/lvrsweb.htm Accessed November 15, 2003.
31. The National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-73.
32. National Emphysema Treatment Trial Research Group. Cost-effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 2003;348:2092-102.
33. Garcia-Aymerich J, Barreiro E, Farrero E, Marrades RM, Morera J, Anto JM. Patients hospitalized with COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 2000;16:1037-42.
34. Vincken W, Van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during one year's treatment with tiotropium. Eur Respir J 2002;19:209-16.
35. Leichtl S, Syed J, Bredenbroker D, Rathgeb F, Wurst W. Efficacy of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Presented at the 98th American Thoracic Society international conference, Atlanta, GA, May 17-22, 2002. Available from http://www.thoracic.org.
36. Vonbank K, Ziesche R, Higenbottam TW, et al. Controlled prospective randomised trial on the effects of pulmonary haemodynamics of the ambulatory long-term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003;58:289-93.
37. Massaro GD, Massaro D. Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats. Am J Physiol 1996;270(2 pt 1):L305-10.
38. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997;3:675-7. (Erratum in Nat Med 1997;3:805.)
39. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997;3:675-7. (Erratum in Nat Med 1997;3:805.)